Academic literature on the topic 'Immune necrotizing myopathies'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Immune necrotizing myopathies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Immune necrotizing myopathies"

1

Mohammed, Abdel Gaffar A., Ayanda Gcelu, Farzana Moosajee, Stella Botha, and Asgar Ali Kalla. "Immune Mediated Necrotizing Myopathy: Where do we Stand?" Current Rheumatology Reviews 15, no. 1 (2018): 23–26. http://dx.doi.org/10.2174/1573397114666180406101850.

Full text
Abstract:
Immune-mediated necrotizing myopathies (IMNMs) are a group of acquired autoimmune muscle disorders which are characterized by proximal muscle weakness, high levels of creatinine kinase, and myopathic findings on electromyogram (EMG). Muscle biopsy in IMNM differentiates it from the other subgroups of Idiopathic Inflammatory Myositis (IIM) by the presence of myofibre necrosis and prominent regeneration without substantial lymphocytic inflammatory infiltrates. Anti-signal recognition particle (SRP) and anti-3hydroxy-3 methylglutarylcoenzyme A reductase (HMGCR) autoantibodies were found in two-th
APA, Harvard, Vancouver, ISO, and other styles
2

Allenbach, Yves, and Olivier Benveniste. "Peculiar clinicopathological features of immune-mediated necrotizing myopathies." Current Opinion in Rheumatology 30, no. 6 (2018): 655–63. http://dx.doi.org/10.1097/bor.0000000000000547.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Akbar, Shalla, Sandhya Dasaraju, and Osama Elkadi. "A Case of Immune-Mediated Necrotizing Myopathy With Associated Skeletal Muscle Involvement by Sarcoid Granulomata: A Rare Association." American Journal of Clinical Pathology 152, Supplement_1 (2019): S69. http://dx.doi.org/10.1093/ajcp/aqz113.078.

Full text
Abstract:
Abstract Skeletal muscle involvement by noncaseating granulomata occurs in a variety of conditions, including sarcoidosis, infections, and rarely in association with primary inflammatory myopathies such as inclusion body myositis (IBM) and dermatomyositis (DM). Sarcoid myopathy is typically asymptomatic; however, a picture of acute myositis with proximal muscle weakness has been described. Immune-mediated necrotizing myopathy (IMNM) is a subgroup of inflammatory myopathies typically presenting with proximal muscle weakness and markedly elevated muscle enzymes, mostly occurring in the setting o
APA, Harvard, Vancouver, ISO, and other styles
4

Pinal-Fernandez, Iago, and Andrew L. Mammen. "Spectrum of immune-mediated necrotizing myopathies and their treatments." Current Opinion in Rheumatology 28, no. 6 (2016): 619–24. http://dx.doi.org/10.1097/bor.0000000000000335.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lee, Jong-Mok. "Immune-Mediated Necrotizing Myopathy: A Review for Clinicians." Journal of Electrodiagnosis and Neuromuscular Diseases 24, no. 3 (2022): 57–61. http://dx.doi.org/10.18214/jend.2022.00087.

Full text
Abstract:
Immune-mediated necrotizing myopathy (IMNM) is a group of inflammatory myopathies showing necrotic and regenerating fibers without noteworthy inflammatory cell infiltration on pathology. The pathologic findings are different from those of dermatomyositis or sporadic inclusion body myositis. Furthermore, the discovery of myositis-specific antibodies in patients with IMNM, such as anti-signal recognition particle or anti-3-hydroxy-3-methylglutaryl-CoA reductase antibodies, has enabled us to expand our knowledge of IMNM. However, the phenotype and pathological findings of IMNM are unremarkable; t
APA, Harvard, Vancouver, ISO, and other styles
6

Knauss, Samuel, Corinna Preusse, Yves Allenbach, et al. "PD1 pathway in immune-mediated myopathies." Neurology - Neuroimmunology Neuroinflammation 6, no. 3 (2019): e558. http://dx.doi.org/10.1212/nxi.0000000000000558.

Full text
Abstract:
ObjectiveTo investigate the relevance of dysfunctional T cells in immune-mediated myopathies. We analyzed T-cell exhaustion and senescence, in the context of programmed cell death protein 1 (PD1)-related immunity in skeletal muscle biopsies from patients with immune-mediated necrotizing myopathy (IMNM), sporadic inclusion body myositis (sIBM), and myositis induced by immune checkpoint inhibitors (irMyositis).MethodsSkeletal muscle biopsies from 12 patients with IMNM, 7 patients with sIBM, and 8 patients with irMyositis were analyzed by immunostaining and immunofluorescence as well as by quanti
APA, Harvard, Vancouver, ISO, and other styles
7

Swafford, Collin, and E. Steve Roach. "Juvenile Dermatomyositis and the Inflammatory Myopathies." Seminars in Neurology 40, no. 03 (2020): 342–48. http://dx.doi.org/10.1055/s-0040-1705120.

Full text
Abstract:
AbstractThe inflammatory myopathies comprise disorders of immune-mediated muscle injury. The histopathology and clinical features help distinguish them. Juvenile dermatomyositis (JDM) is the most common form of myositis in children and adolescents. Children with JDM present with proximal muscle weakness and characteristic rashes. The presentation is similar in children and adults, but JDM is a primary disorder and the adult form often is concerning for a paraneoplastic syndrome. Proximal muscle weakness occurs with dermatomyositis, polymyositis, and immune-mediated necrotizing myopathy, but th
APA, Harvard, Vancouver, ISO, and other styles
8

Mecoli, Christopher A., Arash H. Lahouti, Robert A. Brodsky, Andrew L. Mammen, and Lisa Christopher-Stine. "High-dose cyclophosphamide without stem cell rescue in immune-mediated necrotizing myopathies." Neurology - Neuroimmunology Neuroinflammation 4, no. 5 (2017): e381. http://dx.doi.org/10.1212/nxi.0000000000000381.

Full text
Abstract:
Objective:To describe the experience managing treatment-refractory immune-mediated necrotizing myopathies (IMNM) with high-dose cyclophosphamide (HiCy) therapy.Methods:Five patients with severe refractory IMNM who were treated with HiCy without stem cell rescue were identified. Their medical records were reviewed to assess demographic, clinical, and histologic characteristics as well as response to therapy.Results:Three patients with anti–signal recognition particle (SRP) and 2 patients with anti-HMG-CoA reductase autoantibodies were included. The mean follow-up time after HiCy therapy was 37
APA, Harvard, Vancouver, ISO, and other styles
9

Chiapparoli, Ilaria, Claudio Galluzzo, Carlo Salvarani, and Nicolò Pipitone. "A glance into the future of myositis therapy." Therapeutic Advances in Musculoskeletal Disease 14 (January 2022): 1759720X2211002. http://dx.doi.org/10.1177/1759720x221100299.

Full text
Abstract:
The idiopathic inflammatory myopathies are chronic diseases of the skeletal muscle that comprise various conditions, including dermatomyositis, polymyositis, immune-mediated necrotizing myopathy, and the antisynthetase syndrome. Although there are a number of distinguishing features, all these disorders are characterized by an immune and inflammatory response mainly directed against the muscle. Hence, therapy is geared toward curbing the autoimmune and inflammatory response. A quite wide range of medications are currently available to treat these disorders, but despite all therapeutic progress
APA, Harvard, Vancouver, ISO, and other styles
10

Park, Sunha, Dae-Hyun Jang, Jae-Min Kim, and Nara Yoon. "Prominent Asymmetric Muscle Weakness and Atrophy in Seronegative Immune-Mediated Necrotizing Myopathy." Diagnostics 11, no. 11 (2021): 2064. http://dx.doi.org/10.3390/diagnostics11112064.

Full text
Abstract:
Immune-mediated necrotizing myopathy, a new subgroup of inflammatory myopathies, usually begins with subacute onset of symmetrical proximal muscle weakness. A 35-year-old male presented with severe asymmetric iliopsoas atrophy and low back pain with a previous history of left lower extremity weakness. Although his first left lower extremity weakness occurred 12 years ago, he did not receive a clear diagnosis. Magnetic resonance imaging of both thigh muscles showed muscle edema and contrast enhancement in patch patterns, and the left buttock and thigh muscles were more atrophied compared to the
APA, Harvard, Vancouver, ISO, and other styles
More sources
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!